World-leading challenge study expertise helping deliver scalable, high-quality outpatient vaccine trials in healthy ...

Stallergenes Greer, a global leader in allergy therapeutics, announced today that its Phase IIIb clinical study (YOBI, YOung patients and BIrch allergy), designed to confirm the safety and efficacy of ...

THE WOODLANDS, Texas, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (LXRX) today announced the completion of patient enrollment in the PROGRESS (A Phase 2b, Dose-ranging, Randomized, ...

New results from a study of a drug called Gazyva (obinutuzumab) showed that it significantly reduced disease activity in adults with systemic lupus erythematosus (SLE). The drug was developed by ...